drugset / Trial / NCT01487317
Rivastigmine in the Management of Delirium
Phase 3
Completed
23 enrolled
Assistance Publique - Hôpitaux de Paris
Novartis Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to evaluate the efficacy of an anticholinesterase treatment in patients aged 75 and over, hospitalized with delirium. Study type : Interventional Study design: randomized, double-blind, placebo-controlled study during one month and a 11-month follow-up
Timeline
- Start
- 2011-06
- Primary completion
- 2015-08
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivastigmine | Small molecule | 9.5 mg | Other |